Key points are not available for this paper at this time.
Key Points In the phase 3 TOWER study, exposure-adjusted AE rates were lower for blinatumomab vs SOC chemotherapy in Ph− B-cell r/r ALL patients. These data further support the role of blinatumomab as an efficacious and well-tolerated treatment option for B-cell r/r ALL patients.
Stein et al. (Thu,) studied this question.